Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 19

Results For "Mark"

5301 News Found

Surfix Diagnostics, NKI and CRCbioscreen join forces to validate biomarkers for colorectal cancer screening
News | July 10, 2024

Surfix Diagnostics, NKI and CRCbioscreen join forces to validate biomarkers for colorectal cancer screening

Globally, colorectal cancer impacts 1.9 million people each year, standing as a leading cause of cancer mortality


Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution
News | July 10, 2024

Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution

The built-in AI-trained algorithms will empower users to proactively intervene when their glucose levels require attention and before a complication can even occur


LG Chem enters Chinese osteoarthritis treatment market
News | July 03, 2024

LG Chem enters Chinese osteoarthritis treatment market

Partners with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China


Glenmark and IADVL undertake awareness campaign supporting vitiligo patients in India
Healthcare | June 27, 2024

Glenmark and IADVL undertake awareness campaign supporting vitiligo patients in India

Glenmark released Picture Post Cards on World Vitiligo Day


Glenmark receives ANDA approval for Esomeprazole Magnesium Delayed-Release capsules
Drug Approval | June 12, 2024

Glenmark receives ANDA approval for Esomeprazole Magnesium Delayed-Release capsules

Glenmark's current portfolio consists of 197 products authorized for distribution in the U.S. marketplace


Abbott wins CE mark for dual-chamber leadless pacemaker
News | June 11, 2024

Abbott wins CE mark for dual-chamber leadless pacemaker

Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers


Glenmark receives ANDA approval for Brimonidine Tartrate and Timolol Maleate ophthalmic solution
Drug Approval | May 18, 2024

Glenmark receives ANDA approval for Brimonidine Tartrate and Timolol Maleate ophthalmic solution

According to IQVIATM sales data for the 12-month period ending March 2024, the Combigan Ophthalmic Solution, 0.2%|0.5% market achieved annual sales of approximately $290.0 million